96.81
-1.43 (-1.46%)
| Previous Close | 98.24 |
| Volume | 290,385 |
| Price / Earnings (Forward) | 526.32 |
| Price / Sales | 27.61 |
| Price / Book | 65.68 |
| 52 Weeks Range |
| Profit Margin | -123.28% |
| Operating Margin (TTM) | -143.73% |
| Diluted EPS (TTM) | -2.80 |
| Quarterly Revenue Growth (YOY) | 25.90% |
| Total Debt/Equity (MRQ) | 69.65% |
| Current Ratio (MRQ) | 3.30 |
| Operating Cash Flow (TTM) | -113.49 M |
| Levered Free Cash Flow (TTM) | -96.71 M |
| Return on Assets (TTM) | -51.33% |
| Return on Equity (TTM) | -150.20% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Rhythm Pharmaceuticals, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | -1.5 |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 0.00 |
|
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 0.65% |
| % Held by Institutions | 103.78% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| MEEKER DAVID P | - | 102.44 | -50,000 | -5,122,000 |
| Aggregate Net Quantity | -50,000 | |||
| Aggregate Net Value ($) | -5,122,000 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 102.44 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| MEEKER DAVID P | Officer | 14 Sep 2026 | Automatic sell (-) | 50,000 | 102.44 | 5,122,000 |
| MEEKER DAVID P | Officer | 14 Sep 2026 | Option execute | 50,000 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |